Description

Insulin Aspart Injection (300 units per 3ml prefilled pen) is a fast-acting human insulin analog widely used in laboratory studies focused on glucose metabolism, insulin signaling, and diabetes modeling.

Manufactured by Tonghua Dongbao Pharmaceutical Co., Ltd, this product is produced under strict quality standards and is intended solely for research and laboratory applications.

Each pen delivers precise insulin aspart dosing and is suitable for studies involving insulin response, beta-cell function, and glucose uptake mechanisms in experimental settings.

Note: This product is not intended for human or veterinary use.

Product Parameters

Mechanism & Research Applications

Insulin Aspart is a recombinant analog of human insulin with a single amino acid substitution, allowing for faster absorption and rapid onset. It is commonly used in research to simulate postprandial insulin secretion, evaluate glucose-lowering mechanisms, and assess insulin receptor activity in diabetic model systems.

Key research applications include:

• Pharmacokinetics and pharmacodynamics of rapid-acting insulins

• Glucose uptake and metabolism in adipocytes and hepatocytes

• Diabetes-induced tissue response in animal models

• Pancreatic islet function studies

Safety & Handling

• For laboratory and experimental use only

• Not intended for human or animal use

• Use appropriate lab safety protocols

• Dispose of biohazard materials per local regulations

Disclaimer

This product is intended solely for research and laboratory applications. Not for human, clinical, or veterinary use. Ensure all local regulatory and handling guidelines are followed.